181 related articles for article (PubMed ID: 28872911)
1. What can we learn from the edaravone development program for ALS?
Maragakis NJ
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):98-103. PubMed ID: 28872911
[TBL] [Abstract][Full Text] [Related]
2. Edaravone and its clinical development for amyotrophic lateral sclerosis.
Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
[TBL] [Abstract][Full Text] [Related]
3. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
[TBL] [Abstract][Full Text] [Related]
4. Edaravone in ALS.
Takahashi R
Exp Neurol; 2009 Jun; 217(2):235-6. PubMed ID: 19285071
[No Abstract] [Full Text] [Related]
5. Edaravone (Radicava) for ALS.
Med Lett Drugs Ther; 2017 Nov; 59(1533):180-182. PubMed ID: 29125592
[No Abstract] [Full Text] [Related]
6. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
Sawada H
Expert Opin Pharmacother; 2017 May; 18(7):735-738. PubMed ID: 28406335
[TBL] [Abstract][Full Text] [Related]
7. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
EDARAVONE (MCI-186) ALS 16 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917
[TBL] [Abstract][Full Text] [Related]
8. Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective.
Yeo CJJ; Simmons Z
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):167-172. PubMed ID: 29334251
[TBL] [Abstract][Full Text] [Related]
9. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
Takahashi F; Takei K; Tsuda K; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914
[TBL] [Abstract][Full Text] [Related]
10. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
11. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918
[TBL] [Abstract][Full Text] [Related]
12. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.
Takei K; Tsuda K; Takahashi F; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):64-70. PubMed ID: 28872916
[TBL] [Abstract][Full Text] [Related]
13. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
Ikeda K; Iwasaki Y
PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
[TBL] [Abstract][Full Text] [Related]
14. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
Kalin A; Medina-Paraiso E; Ishizaki K; Kim A; Zhang Y; Saita T; Wasaki M
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):71-79. PubMed ID: 28872919
[TBL] [Abstract][Full Text] [Related]
15. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.
Takei K; Takahashi F; Liu S; Tsuda K; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):49-54. PubMed ID: 28872913
[TBL] [Abstract][Full Text] [Related]
16. July 2017 ENCALS statement on edaravone.
Al-Chalabi A; Andersen PM; Chandran S; Chio A; Corcia P; Couratier P; Danielsson O; de Carvalho M; Desnuelle C; Grehl T; Grosskreutz J; Holmøy T; Ingre C; Karlsborg M; Kleveland G; Koch JC; Koritnik B; KuzmaKozakiewicz M; Laaksovirta H; Ludolph A; McDermott C; Meyer T; Mitre Ropero B; Mora Pardina J; Nygren I; Petri S; Povedano Panades M; Salachas F; Shaw P; Silani V; Staaf G; Svenstrup K; Talbot K; Tysnes OB; Van Damme P; van der Kooi A; Weber M; Weydt P; Wolf J; Hardiman O; van den Berg LH
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Nov; 18(7-8):471-474. PubMed ID: 28975816
[No Abstract] [Full Text] [Related]
17. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
[TBL] [Abstract][Full Text] [Related]
18. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.
Nagase M; Yamamoto Y; Miyazaki Y; Yoshino H
Redox Rep; 2016 May; 21(3):104-12. PubMed ID: 26191780
[TBL] [Abstract][Full Text] [Related]
19. Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients.
Ohta Y; Yamashita T; Nomura E; Hishikawa N; Ikegami K; Osakada Y; Matsumoto N; Kawahara Y; Yunoki T; Takahashi Y; Takamiya M; Tadokoro K; Sasaki R; Nakano Y; Tsunoda K; Sato K; Omote Y; Takemoto M; Abe K
J Neurol Sci; 2020 Aug; 415():116906. PubMed ID: 32446009
[TBL] [Abstract][Full Text] [Related]
20. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Abe K; Itoyama Y; Sobue G; Tsuji S; Aoki M; Doyu M; Hamada C; Kondo K; Yoneoka T; Akimoto M; Yoshino H;
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):610-7. PubMed ID: 25286015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
